منابع مشابه
Update on antiphospholipid syndrome.
This review addresses new clinical issues (revealed at the 2006 Sydney update of the 1999 Sapporo Classification criteria; cardiac, renal, and multiple sclerosis-like disease; catastrophic syndrome), mechanisms of action of antiphospholipid antibody (very likely complement mediated), current therapies (moderate dose warfarin recommended for prophylaxis, aspirin not recommended for primary proph...
متن کامل[Antiphospholipid syndrome - an update on diagnosis and treatment].
Antiphospholipid syndrome (APS) was described by Hughes et al in 1986 and then by Harris et al in 1987. The symptoms of disease are related to the presence of autoantibodies directed against plasma and serum proteins that form complexes with phospholipids of cell membranes. The immunologic process involving vascular endothelium, thrombocytes and coagulation factors is responsible for enhancemen...
متن کاملCritical Update of the Antiphospholipid Syndrome Criteria
Diagnosis of Antiphospholipid Syndrome (APS) is made when vascular thrombosis or pregnancy morbidity occur in patients with circulating antiphospholipid antibodies [lupus anticoagulant (LA) and/or IgG/IgM anticardiolipin (aCL) and/or IgG/IgM anti2glycoprotein I (a 2GPI) antibodies]. Although each test may identify different autoantibodies, a single positive test makes the diagnosis possible whe...
متن کاملAntiphospholipid syndrome: an overview.
Antiphospholipid antibodies are a heterogeneous group of autoantibodies that are detected by immunoassays and functional coagulation tests. The antigenic targets are negatively charged phospholipids and serum phospholipid-binding proteins. The latter antibodies are frequently associated with thrombosis, fetal loss and other clinical manifestations of the antiphospholipid syndrome. These antibod...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Clinical Investigation
سال: 2015
ISSN: 0014-2972
DOI: 10.1111/eci.12449